Saturday 17 October 2026
Export NEOG’s income statement to Excel — free account
Neogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025. In the quarter to August 2026, revenue grew 6.51%, EPS fell 132.1%, free cash flow grew 135.8% and total debt fell 2.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.81
0.46
−3.75%
Follow NEOG
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | 6 |
| (25.25%) | (25.56%) | (0.38%) | (2.67%) | ||
| (16.26%) | (16.46%) | (0.23%) | (1.68%) | ||
ROIC |
(14.24%) | (14.53%) | (0.50%) | (0.17%) | |
Return on Tangible Assets |
(79.31%) | (78.93%) | (1.02%) | (7.36%) | |
Average Days of Receivables |
54.73 | 57.48 | 61.56 | 56.24 | |
Free Cash Flow per Share |
(0.08) | 0.03 | 0.15 | 0.23 | |
Free Cash Flow |
(17.87) | 6.30 | 32.00 | 49.85 | |
Capital Expenditures |
(84.02) | (63.10) | (51.20) | (35.40) | |
| Other line items | |||||
Cash ROIC |
(0.59%) | 0.21% | 1.04% | 1.64% | |
Accounts Receivable Turnover |
5.95 | 5.86 | 5.80 | 6.44 | |
Accounts Payable Turnover |
6.67 | 6.47 | 5.82 | 6.03 | |
Inventory Turnover |
2.63 | 2.60 | 2.76 | 2.74 | |
Average Days of Payables |
48.38 | 57.54 | 62.51 | 60.91 | |
Days of Inventory on Hand |
124.93 | 123.72 | 114.03 | 114.69 | |
Tax Rate |
(0.02) | (0.03) | (0.12) | (0.17) | |
Research and Development Expense of Revenue |
2.33% | 2.27% | 2.11% | 2.24% | |
Selling, General and Administrative Expense of Revenue |
46.99% | 47.30% | 47.30% | 45.99% | |
Share Based Compensation of Revenue |
2.02% | 1.69% | 1.54% | 1.31% | |
Interest Coverage |
(9.95) | (10.61) | (0.37) | (0.13) | |
Operating CF/Net income |
(0.11) | (0.11) | (10.53) | (1.52) | |
Depreciation/Fixed assets |
2.19 | 2.18 | 0.38 | 0.38 | |
Capex/Depreciation |
(0.12) | (0.09) | (0.41) | (0.28) | |
Revenue per Share |
4.05 | 4.00 | 4.00 | 4.05 | |
Operating CF per Share |
0.30 | 0.32 | 0.38 | 0.39 | |
Capex per Share |
(0.39) | (0.29) | (0.24) | (0.16) | |
Capex to Sales |
0.10 | 0.07 | 0.06 | 0.04 |
Columns are period end dates · fundamentals updated 13 Oct 2026